THE FIVE DREADED WORDS
We didn't get it all
But it doesn't need to be this way
THE FIVE DREADED WORDS
We didn't get it all
But it doesn't need to be this way

TumorMAP™ features an innovative and transformational advanced imaging technology that provides on-demand objective insights into cancer visualization. Optically driven sensors powered by AI allow for integration into core robotic and MIS technologies, creating potentially transformative capabilities.

The Tumor Margin Assessment and Profiling System, TumorMAP™, is a multi-spectral imaging system that uses ultraviolet-excited autofluorescence and optical reflectance to assess tissue indicative of cancer during surgical procedures, beginning with breast-conserving surgery.

The platform offers an intuitive user interface and is seamlessly integrated into the surgical workflow. In addition, the platform provides dynamic information to enable surgeons to visualize tissue previously invisible to them, thus improving the quality of surgery!

  • Large touch screen display
  • Ultra High Definition Resolution
  • Connectivity to PACS and EMR
  • Automated tissue sample tray
  • Report generation
  • Non-toxic and non-destructive to tissue
*TumorMAP™ is not yet cleared for use by the FDA.
The Data Tells us we Need to Improve the Precision of Cancer Resection

Breast Conservation Surgeries (BCS)

Up
to

35%

15-35% of BCS lumpectomies require a second surgery which often presents increased risk of complications ²

Transurethral Resection of Bladder Tumor (TURBT)

30-50%

of TURBT resections are incomplete, contributing to a higher risk of residual disease, early recurrence, and increased mortality¹

Radical Prostatectomies (RP)

25%

of RP procedures result in positive surgical margins, leading to a 2 to 3 fold increased in risk of biochemical recurrence³

1. Quality of diagnostic staging in patients with bladder cancer: A process‐outcomes link. K Chamie, et al. 3, 2015, Cancer, Vol. 121
2. A randomized, controlled trial of Cavity Shave margins in breast cancer. Chagpar, A. B et al. (2015). New England Journal of Medicine, 373(6)
3. Frequency of Positive Surgical Margin at Prostatectomy and Its Effect on Patient Outcome. K. Iczkowski, M. Scott. Prostate Cancer, Vol. 2011

  1. Quality of diagnostic staging in patients with bladder cancer: A process‐outcomes link. K Chamie, et al. 3, 2015, Cancer, Vol. 121
  2. A randomized, controlled trial of Cavity Shave margins in breast cancer. Chagpar, A. B et al. (2015). New England Journal of Medicine, 373(6)
  3. Frequency of Positive Surgical Margin at Prostatectomy and Its Effect on Patient Outcome. K. Iczkowski, M. Scott. Prostate Cancer, Vol. 2011

TumorMAP™ Technology

Visualizing Tissue Type, Cancer Boundaries, and Critical Structures Intraoperatively without Dyes

TumorMAP™ quickly identifies tissue/disease state based on its intrinsic/endogenous biomolecular characteristics

It can be applied to all solid tumor cancers and other target tissue types

TumorMAP™ powered by OncoSIGHT AI relies on the intersection of the natural biochemical characteristics of tissue, multispectral imaging and AI, and is under development to make a difference for patients across multiple disease areas.

Indication

Pre-clinical research

OncoSIGHT AI training
OncoSIGHT AI validation

Feasibility Study

Pivotal Study

FDA Approval

breast
bladder
PROSTATE

CytoVeris is proving what’s possible during cancer surgery.

Be the first to know

Find Us

Contact Us

Media inquiries, please contact
[email protected]

Copyright © 2022 CytoVeris Inc. All rights reserved.

“CYTOVERIS NAMED "MURPHY'S INNOVATOR OF THE MONTH"

CytoVeris is a medical device company developing optical smart cancer imaging technologies designed to improve the clinical outcomes of patients undergoing certain cancer removal procedures by using enhanced clinical decision-making during surgery.